ANAVEX2-73 oral liquid ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 156 | レット症候群 | 1 |
156. レット症候群
臨床試験数 : 44 / 薬物数 : 61 - (DrugBank : 23) / 標的遺伝子数 : 57 - 標的パスウェイ数 : 83
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04304482 (ClinicalTrials.gov) | July 1, 2020 | 8/3/2020 | ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome | ANAVEX2-73-RS-003 is a Phase 2/3, Double-blind, Randomized, Placebo-controlled Safety and Efficacy Study in Pediatric Patients With RTT | Rett Syndrome | Drug: ANAVEX2-73 oral liquid;Drug: Placebo oral liquid | Anavex Life Sciences Corp. | Anavex Australia Pty Ltd.;Anavex Germany GmbH | Active, not recruiting | 5 Years | 17 Years | Female | 92 | Phase 2/Phase 3 | Australia;Canada;United Kingdom |